| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7332183 | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Oct, 2025
(1 year, 11 months from now) | |
|
US7332183 (Pediatric) | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Apr, 2026
(2 years from now) | |
Treximet is owned by Currax.
Treximet contains Naproxen Sodium; Sumatriptan Succinate.
Treximet has a total of 2 drug patents out of which 0 drug patents have expired.
Treximet was authorised for market use on 15 April, 2008.
Treximet is available in tablet;oral dosage forms.
Treximet can be used as treatment of migraine; acute treatment of migraine.
The generics of Treximet are possible to be released after 02 April, 2026.
Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 15 April, 2008
Treatment: Treatment of migraine; Acute treatment of migraine
Dosage: TABLET;ORAL
TREXIMET family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic